Latest Mental Health News

TrivarX Limited has exercised its option to acquire the innovative Stabl-Im brain imaging technology, aiming to revolutionize early detection of brain tumours pending shareholder approval.

Tryptamine Therapeutics has initiated the world’s first clinical trial of its IV-infused psilocin drug, TRP-8803, targeting Binge Eating Disorder, alongside a pioneering EEG biomarker collaboration and new funding.

TrivarX has reported promising interim results from its US veteran-focused mental health trial using ECG technology, while progressing a strategic acquisition of novel brain tumor imaging IP to broaden its diagnostic portfolio.

Future Generation announces CEO Caroline Gurney will step down in early 2026, leaving behind a legacy of strong investment returns and $100 million donated to Australian non-profits. An executive search is underway to find her successor.

Image Resources NL reported a strong third quarter in 2025 with significant increases in heavy mineral concentrate production and sales at its Atlas project, despite challenging weather and port delays. However, the company has trimmed its shipment guidance for the year due to weaker market conditions and logistical issues.

Doctor Care Anywhere reports a 7.5% rise in consultations excluding secondary care and sustains positive cashflow for the second consecutive quarter, reaffirming ambitious medium-term growth targets.

Medibank has set ambitious goals to triple its health segment earnings by FY30, expand its private health insurance market share, and double its health engagement, signaling a strategic pivot towards integrated, technology-driven care.

Global Health Limited has accelerated its MasterCare+ SaaS platform rollout, integrating AI to streamline operations and reduce staff by 10%, while reporting a 25% EBIT improvement despite a delayed R&D refund impacting cash flow.

Emyria reports strong revenue growth driven by expanded insurer-funded mental health programs, marking a significant step in national access to evidence-based PTSD and treatment-resistant depression care.

BlinkLab Limited has completed its U.S. pilot study for the Dx 1 smartphone-based autism diagnostic device, demonstrating strong accuracy and securing FDA alignment for its pivotal trial. The results mark a significant step toward transforming early neurodevelopmental diagnostics.

TrivarX has completed recruitment of 60 patients in its US veteran-focused mental health trial, advancing validation of its novel single-lead ECG algorithm for depression screening. Positive interim results from 27 patients set the stage for full data release and commercial discussions.

TrivarX Limited has announced the acquisition of Stabl-Im, a novel stable isotope MRI technology for early brain tumor detection, backed by a $4.2 million capital raise including investment from biotech leader Dr Daniel Tillett.